Your browser is no longer supported. Please, upgrade your browser.
Settings
ALRN Aileron Therapeutics, Inc. daily Stock Chart
ALRN [NASD]
Aileron Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.13 Insider Own16.40% Shs Outstand17.45M Perf Week29.82%
Market Cap25.83M Forward P/E- EPS next Y-2.12 Insider Trans0.00% Shs Float6.98M Perf Month35.78%
Income-31.40M PEG- EPS next Q-0.51 Inst Own20.60% Short Float0.54% Perf Quarter-47.14%
Sales- P/S- EPS this Y-24.30% Inst Trans- Short Ratio0.27 Perf Half Y-67.61%
Book/sh1.77 P/B0.84 EPS next Y2.80% ROA-70.00% Target Price15.67 Perf Year-84.62%
Cash/sh1.60 P/C0.93 EPS next 5Y2.10% ROE-85.00% 52W Range0.52 - 9.88 Perf YTD76.19%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-85.02% Beta-
Dividend %- Quick Ratio2.50 Sales past 5Y- Gross Margin- 52W Low184.62% ATR0.23
Employees15 Current Ratio2.50 Sales Q/Q- Oper. Margin- RSI (14)58.09 Volatility26.19% 25.02%
OptionableNo Debt/Eq0.19 EPS Q/Q-18.60% Profit Margin- Rel Volume2.05 Prev Close1.47
ShortableYes LT Debt/Eq0.00 EarningsFeb 06 AMC Payout- Avg Volume138.89K Price1.48
Recom1.00 SMA2052.25% SMA50-6.33% SMA200-58.03% Volume277,394 Change0.73%
Jul-24-17Initiated William Blair Outperform
Jul-24-17Initiated Jefferies Buy $20
Jul-24-17Initiated BofA/Merrill Buy $19
Jan-16-19 12:47PM  Aileron Therapeutics Commences Enrollment in a Phase 2a Expansion Cohort for ALRN-6924 in Combination with Pfizers IBRANCE® (palbociclib) in Patients with MDM2-Amplified Cancers GlobeNewswire +28.89%
Dec-21-18 11:33AM  Could The Aileron Therapeutics, Inc. (NASDAQ:ALRN) Ownership Structure Tell Us Something Useful? Simply Wall St. -13.92%
Dec-04-18 09:13AM  Aileron Presents Interim ALRN-6924 Data from PTCL, MDS, and AML Clinical Trials at the 60th Annual American Society of Hematology Meeting GlobeNewswire -7.62%
Nov-28-18 10:22AM  Aileron Inks Collaboration Deal With Pfizer for Cancer Combo Zacks
Nov-27-18 08:00AM  Aileron Enters Clinical Trial Collaboration with Pfizer to Evaluate ALRN-6924 in Combination with IBRANCE® (palbociclib) in MDM2-Amplified Cancers GlobeNewswire +9.84%
Nov-19-18 08:25AM  Recent Analysis Shows Arcimoto, ADOMANI, Lipocine, Aileron Therapeutics, Allena Pharmaceuticals, and Perma-Fix Environmental Services Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Nov-07-18 04:10PM  Aileron Therapeutics Reports Third Quarter 2018 Financial Results GlobeNewswire
Nov-05-18 04:05PM  Aileron Therapeutics Appoints Vojislav Vukovic, MD, PhD, as Chief Medical Officer GlobeNewswire
Nov-01-18 04:05PM  Aileron Therapeutics Announces Clinical Trial Collaboration with Dana-Farber/Boston Childrens Cancer and Blood Disorders Center GlobeNewswire -10.64%
Oct-30-18 04:05PM  Aileron Therapeutics to Report Third Quarter 2018 Financial Results on November 7, 2018 GlobeNewswire
Oct-19-18 08:00AM  Aileron Announces Poster Presentations at Two Scientific Conferences in November GlobeNewswire
Sep-06-18 09:00AM  Aileron Therapeutics Announces the Appointment of Dr. Manuel Aivado as Chief Executive Officer GlobeNewswire -11.26%
Aug-07-18 04:15PM  Aileron Therapeutics Reports Second Quarter 2018 Financial Results GlobeNewswire
Aug-02-18 07:00AM  Aileron Therapeutics to Present at the Canaccord Genuity 38th Annual Growth Conference GlobeNewswire
Jul-31-18 07:00AM  Aileron Therapeutics to Report Second Quarter 2018 Financial Results on August 7, 2018 GlobeNewswire
May-29-18 07:00AM  Aileron Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference GlobeNewswire
May-22-18 05:00AM  Aileron Therapeutics Announces Publication of ALRN-6924 Nonclinical Data in T-cell Lymphomas by Researchers at Dana-Farber Cancer Institute GlobeNewswire
May-15-18 04:05PM  Aileron Therapeutics Announces Changes to Management GlobeNewswire
May-09-18 04:03PM  Aileron Therapeutics Reports First Quarter 2018 Financial Results GlobeNewswire
Apr-11-18 04:05PM  Aileron Therapeutics Announces Publication by Researchers at Albert Einstein College of Medicine of ALRN-6924 Nonclinical Data in Acute Myeloid Leukemia GlobeNewswire +11.04%
Apr-02-18 04:09PM  Aileron Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results GlobeNewswire
Mar-28-18 07:00AM  Aileron Therapeutics Announces Expansion of Scientific Advisory Board GlobeNewswire
Mar-19-18 07:00AM  Aileron Therapeutics Appoints Jeffrey A. Bailey to its Board of Directors GlobeNewswire +7.18%
Dec-11-17 04:30PM  Aileron Therapeutics Presents New Data on ALRN-6924 in Oral Presentations at 2017 American Society of Hematology Meeting GlobeNewswire
Nov-09-17 04:18PM  Aileron Therapeutics Reports Third Quarter 2017 Financial Results GlobeNewswire
Nov-01-17 09:19AM  Aileron Therapeutics Announces Oral Presentations on Lead Product Candidate ALRN-6924 at the 59th American Society of Hematology Annual Meeting GlobeNewswire +9.55%
Oct-05-17 06:40AM  Boston biotech developing obesity drug pulls down $120M in IPO American City Business Journals
Sep-19-17 07:00AM  Aileron Therapeutics Added to the Russell 2000, Russell 3000 and Russell Microcap Indexes GlobeNewswire
Aug-24-17 07:00AM  Aileron Therapeutics Announces Presentation of Preclinical Data with ALRN-6924 at the International Society of Experimental Hematology Annual Scientific Meeting GlobeNewswire
Aug-10-17 04:11PM  Aileron Therapeutics Reports Second Quarter 2017 Financial Results GlobeNewswire
Aug-03-17 07:00AM  Aileron Therapeutics to Present at Canaccord Genuity 37th Annual Growth Conference GlobeNewswire
Jul-19-17 09:21AM  [$$] Novartis, Glaxo and Lilly Bigly Back New Biotech Barrons.com
Jul-07-17 12:46PM  The Largest Insider Trades of the Week GuruFocus.com
Jul-03-17 01:02PM  Here's the Latest on Four New Biotech IPOs TheStreet.com +13.00%
Jun-28-17 10:06PM  Aileron Therapeutics Announces Pricing of Initial Public Offering GlobeNewswire
Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside. It also develops next generation wild type p53 reactivator that is in preclinical stage for the treatment of solid and liquid tumors. Aileron Therapeutics, Inc. has a collaboration agreement with Dana-Farber/Boston Children's Cancer and Blood Disorders Center for an open-label, multi-center, pediatric phase 1 clinical trial of ALRN-6924; and Pfizer to evaluate the combination of ALRN-6924 and IBRANCE in MDM2-amplified cancers. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was founded in 2001 and is based in Cambridge, Massachusetts.